RxDoctor Payments Data

William Bone, MD

Infectious Disease · Panama City, FLNPI 1043288285

Payments from drug & device makers

$39,063in general payments, 2019–2025

Across 253 payments — averaging $154.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$33K
  • AbbVie$4K
  • Viiv Healthcare Company$1K
  • Merck$418
  • Insmed, Inc.$230
  • Theratechnologies Inc.$168
  • plus $608 from 10 others

What the payments were for

  • Speaking & faculty fees$32,18682%
  • Travel & lodging$1,9095%
  • Food & beverage$4,84512%
  • Education$1230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,063 in reported general payments places this provider in the 85th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$237,489
Medicare patients
455
Services billed
2,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala280$1,169,129
GenvoyaElviteg/Cob/Emtri/Tenof Alafen83$325,640
TriumeqAbacavir/Dolutegravir/Lamivudi65$248,463
CabenuvaCabotegravir/Rilpivirine18$118,837
DovatoDolutegravir Sodium/Lamivudine34$98,536
JulucaDolutegravir/Rilpivirine27$95,069
DescovyEmtricitabine/Tenofov Alafenam37$85,124
TivicayDolutegravir Sodium23$55,413
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$43,478
ViraceptNelfinavir Mesylate12$19,375
Darunavir11$18,590
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$18,231
OzempicSemaglutide12$10,731
EliquisApixaban15$9,052
Vancomycin Hcl49$5,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$32,546$1,579,893400 claims
Viiv Healthcare CompanyTriumeq, Cabenuva, Dovato, Juluca, Tivicay$1,073$616,317167 claims
PfizerEliquis$40$9,05215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →